Sign in
CompletedNo phase

The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus

Key facts

Who runs it
University Hospital Hradec Kralove
Where
Czechia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
41 people enrolled
Started
7 Dec 2023
Ended
27 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lumbar puncture
  • External lumbar drainage
  • Lumbar infusion test
  • Ventriculo-peritoneal shunt placement
  • General Anesthesia
  • Prechamber puncture
  • Blood sampling #1
  • Blood sampling #2
  • Blood sampling #3
  • Blood sampling #4 and #5
Record updated
2 October 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • In group A:; Patients with diagnosed communicating hydrocephalus; MMSE > 10 points; Absence of any structural laesion on MRI or CT; Accepted Informed consent
  • In group B:; MMSE > 10 points; Absence of any structural laesion on MRI or CT; Accepted Informed consent; Elective spinal surgery without affecting dural sac and the spinal cord; Surgery shorter than 120 minutes of lasting the general anesthesia

Who cannot take part

  • Surgery lasting more than 120 minutes
  • Pre-existing other type of demetia (m. Alzheimer, vascular dementia)
  • Non-communicating hydrocephalus
  • Structural laesion on MRI or CT (tumour, contusion, aneurysm)
  • MMSE < 10 points
  • Life-expectancy shorter than 1 year
  • Blood loss more than 500 ml
  • Opening of dural sac (liquororhea)
  • Adverse events during general anestesia: MAP<60 mm Hg more than 5 minutes, arythmia with need for farmacological treatment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Neurofilament Light Chain Protein (NfL) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (Alzheimer's disease, Multiple Sclerosis, etc.), inflamation (HIV) or trauma. Its role as biomarker thus offers a possibility to predict and manage diseases associated with neuronal damage. Therefore our aim is to investigate the changes in level of NfL in hydrocephalus and to find its role in management of treatment in hydrocephalus.

The 2 groups in the trial

  • Study group ATreatment being tested

    Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anestezia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmate the diagnosis and responsivity to VP shunt placement.

    Treatment: Lumbar puncture, External lumbar drainage, Lumbar infusion test, Ventriculo-peritoneal shunt placement, General Anesthesia, Prechamber puncture, Blood sampling #1, Blood sampling #2, Blood sampling #3, and Blood sampling #4 and #5

  • Study group BExisting treatment, for comparison

    Patients without diagnosed hydrocephalus undergoing short spinal surgery without affecting dural sac (e.g. anterior cervical discectomy and fusion or lumbar disc herniation or lumbar decompression) in general anestezia.

    Treatment: General Anesthesia, Blood sampling #1, Blood sampling #2, and Blood sampling #3

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Role of Neurofilament Light (NfL) in Management of Patients With Hydrocephalus: A Pilot Study
Record updated
2 October 2025